Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. - Wikidata - wikimedia - TriplyDB

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

http://www.wikidata.org/entity/Q34274124

about

Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications The Link between Autoimmunity and Lymphoma: Does NOTCH Signaling Play a Contributing Role?The c-Rel transcription factor and B-cell proliferation: a deal with the devil New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.Hodgkin lymphoma: an update on its biology with new insights into classification.Oncogenic activation of NF-kappaB.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.EBV in Hodgkin Lymphoma.The molecular pathogenesis of Hodgkin lymphoma.Hodgkin lymphoma.The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas NF-κB and cancer: a paradigm of Yin-Yang.Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.Mechanisms of B-cell lymphoma pathogenesis.IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression.Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival Gene expression levels in normal human lymphoblasts with variable sensitivities to arsenite: identification of GGT1 and NFKBIE expression levels as possible biomarkers of susceptibility.Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell.Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.A high throughput experimental approach to identify miRNA targets in human cells.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Anti-Metastatic Effect of Semi-Purified Nuphar Lutea Leaf Extracts Genetic background and evolution of relapses in aggressive B-cell lymphomas.Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.Bfl-1 is a crucial pro-survival nuclear factor-κB target gene in Hodgkin/Reed-Sternberg cells.CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB.Modulation of transcription factor NF-kappaB in Hodgkin's lymphoma cell lines: effect of (-)-epicatechin.Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.Genetic variation in toll-like receptors and retinoic acid-inducible gene I and outcome of hepatitis C virus infection: a candidate gene association study.Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.Recurrent genetic defects in classical Hodgkin lymphoma cell lines.NF-κB in Hematological Malignancies.NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.

P2860

Q27011510-408BA4B1-151C-445F-A6CE-31681019EB3E Q28082490-70C3FA0C-4566-442A-8D49-5F148EDE2176 Q28241767-E84186D3-4DD7-4054-8E81-9FFAC2CD2218 Q30466798-B84D9604-8EC5-4D84-A4AE-CAFAA9675826 Q33375800-6AB48D49-C779-4B40-BA9F-A5B1946D071F Q33432504-E4663B8A-35AA-4A6B-AC10-C386E9B4FBFA Q33588862-0134C8D4-E171-4D38-9508-C6D87E9AEADF Q33849388-C99E02AF-7BDE-4B2E-ABCA-CDD18B665DA2 Q33889168-6D9BD4C9-E332-432F-A952-D3AD64E7B521 Q34235750-6B43BE26-AB2D-4A69-A56A-97BB054CD4D2 Q34294390-C5E8E3B4-CA2D-43FE-B3B0-7B383B707B23 Q34480682-10D614D9-1536-4D3B-90FE-D80F58720CFA Q34549468-FC5FD258-AA24-4F98-A688-C8160F0352DC Q34626576-D261DA71-6006-458C-A15D-BC1AAD29632F Q34643277-F809A6C1-7881-498D-A88B-FEC07A71AC74 Q34694988-97062148-A1DB-40BD-B21B-F79AEBB99C63 Q35232248-D817AB74-6597-46D3-8505-44BBEC6238B7 Q35671227-E5A35276-134E-4D6D-9FAD-242A735C147C Q36085626-A330B186-9E5B-45CA-AD88-161EE19A7460 Q36117584-56B3C1F4-72DB-48E0-89BF-74A27CC0181D Q36370847-CA115BA5-BA9A-4310-B8ED-AEF0428164CD Q36546222-90BB3E34-2721-4D5C-A90A-73CFC0CE2A0E Q37004635-F77F4F17-9F29-4FB0-88DB-7A4CDFE3F555 Q37683382-3ECDBB69-B360-40A7-96E3-0AFCEAE62B57 Q38182355-A0CFFFC0-5FE7-46BB-9D5B-57D669DEB95C Q38350728-6D9651D8-7832-42FB-967B-1DDB79BDFE59 Q38557033-291FE8C0-5A0E-4BA3-A603-2FA8AF741565 Q39332430-B2ED44A2-C6C2-4D56-8008-D22E1B974B65 Q39336821-066452D7-CFCC-4A69-B0DB-DDF2E52DFE15 Q39370671-2D400B81-A8AE-4B10-82AA-22C0A720D1C1 Q39468269-FC6F2CFC-AA68-4110-A30A-56A8020B6949 Q39558930-A0DE0E75-5AC9-4D83-9795-9E9C6B72EBFC Q39850171-6A836220-F3BD-4FB9-8525-DB65E9E1AD47 Q40224980-1F03FE3E-6AB2-4469-8137-0A397B07556D Q40443980-6E59D444-1BF3-4965-A0F1-6167EF1EA9B4 Q42240906-2FB56368-1157-4B01-BD10-5D0E07871986 Q49592738-97AE0983-0928-4397-B506-E5BF973106B3 Q50657891-411BC6C3-E63B-4FCC-9D2F-659FEF36306C Q54147337-E645242F-C26A-4097-8A80-B6CF351DCC71 Q54247368-1404BC13-5EFA-4187-8DB1-547CDA657071

P2860

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

http://www.wikidata.org/entity/Q34274124

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@ast

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@en

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@nl

type

label

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@ast

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@en

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@nl

prefLabel

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@ast

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@en

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@nl

P1433

Q34274124-C3D166D2-4999-4F50-9B70-54AF477477AE

P1476

Q34274124-369DF2F0-B968-4BEF-B45B-0336BB40248E

P2093

Q34274124-30C96D31-1235-4016-800D-A25E7D067D7B

Q34274124-501E19F6-F3D3-4576-9838-DDF8A39C4246

Q34274124-D00ABECE-F01E-475A-BFB2-B33215582025

Q34274124-E899E838-8DF7-4FFF-9AC3-979E625B6A35

Q34274124-EAEA4F99-A43C-4B41-82AA-55D00904BCFC

Q34274124-F899E06C-D1F3-430F-A92E-9466F31AE89C

P2860

Q34274124-00BC0171-8F71-44C9-A0F6-0FBDC77F55CA

Q34274124-1E946E81-8943-4852-B0F1-DB85911D90F4

Q34274124-20D22018-677C-489B-9134-A181D3094C96

Q34274124-272BAEE1-F651-42FC-AD78-A540F180F259

Q34274124-2A9FB813-856D-40A8-9F08-0CA647C651CF

Q34274124-4659D88B-0A27-4B2A-A4B6-3B07E32BB9CF

Q34274124-4D2C0078-8749-44D1-9240-8C61DAF37511

Q34274124-7CEDD422-CEAD-4D64-9973-D2A89B4B3CF4

Q34274124-8B228D65-E778-44FC-90CC-A3744F168690

Q34274124-A10E876C-9AD5-4CF3-AEB6-A7C98277D6EA

P304

Q34274124-D3229145-35A0-4BA5-8A26-460821293F23

P31

Q34274124-DA044DE9-55E2-4339-8574-07606469DD7B

P356

Q34274124-98EA00BF-5DE6-42A2-B111-966F51931758

P433

Q34274124-182A0EFD-C4F8-4238-8B08-B3BFD1490808

P478

Q34274124-1C48DF1E-B85E-477F-8E6A-06DE27CB6B9A

P50

Q34274124-5BADD2C0-6339-444F-8F71-049CBECCC419

Q34274124-62D2679B-007C-44E2-BA15-6EEE0EDBB9E8

Q34274124-FA3F6AD2-353E-44FE-8050-A1149349F7C5

P577

Q34274124-A5B5EB54-7CC7-49CB-A80D-ABAFF8D199CE

P5875

Q34274124-6D624120-8027-47A1-A24C-D3C36B82A7AB

P698

Q34274124-1E593974-322B-41BD-896D-A5BB52AFCA76

P356

P1433

The Journal of Pathology

P1476

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.

@en

P2093

Antje Haeffker

http://www.w3.org/2001/XMLSchema#string

Bernd Dörken

http://www.w3.org/2001/XMLSchema#string

Florian Emmerich

http://www.w3.org/2001/XMLSchema#string

Harald Stein

http://www.w3.org/2001/XMLSchema#string

Kurt Bommert

http://www.w3.org/2001/XMLSchema#string

Magnus S Vry

http://www.w3.org/2001/XMLSchema#string

P2860

The NF-kappa B and I kappa B proteins: new discoveries and insights

I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity.

Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B

A compensatory base change in U1 snRNA suppresses a 5' splice site mutation

The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation.

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.

Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.

Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.

Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells.

P304

413-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.1454

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

Sebastian Theurich

Konstanze Döhner

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5373920

http://www.w3.org/2001/XMLSchema#string

P698

14595753

http://www.w3.org/2001/XMLSchema#string